Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00827489
NCT00827489
Terminated
Phase 1

Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTC-867 Administered Orally to Healthy Subjects

Wyeth is now a wholly owned subsidiary of Pfizer0 sites72 target enrollmentJanuary 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealthy Subjects
InterventionsHTC-867Placebo
DrugsHTC-867

Overview

Phase
Phase 1
Intervention
HTC-867
Conditions
Healthy Subjects
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment
72
Primary Endpoint
Safety as measured by the number of adverse events and serious adverse events. Tolerability as measured by occurrence of dose limiting toxicities.
Status
Terminated
Last Updated
16 years ago
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSimilar Trials

Overview

Brief Summary

The purpose of this study is to assess the safety and tolerability of ascending single oral doses of HTC-867 in healthy young and elderly subjects. This study will also evaluate the way the drug enters and leaves the blood and tissues over time and how the drug acts on and in the body in a fasted and fed state.

Registry
clinicaltrials.gov
Start Date
January 2009
End Date
April 2009
Last Updated
16 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

HTC-867

Intervention: HTC-867

Placebo

Intervention: Placebo

Outcomes

Primary Outcomes

Safety as measured by the number of adverse events and serious adverse events. Tolerability as measured by occurrence of dose limiting toxicities.

Time Frame: 5 months

Secondary Outcomes

  • Pharmacokinetic and pharmacodynamic parameters.(5 months)

Similar Trials

Withdrawn
Phase 1
Study Evaluating Single Doses of GAP-134Healthy Subjects
NCT00820521Wyeth is now a wholly owned subsidiary of Pfizer
Completed
Phase 1
Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing PotentialFibroid
NCT00427544Wyeth is now a wholly owned subsidiary of Pfizer
Completed
Phase 1
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 Administered to Healthy Japanese FemalesUterine Leiomyomata (Fibroids)
NCT00444704Wyeth is now a wholly owned subsidiary of Pfizer
Completed
Phase 1
Study Evaluating the Safety and Pharmacokinetics of Ascending Single IV Doses of ERB-257Healthy Subjects
NCT00722501Wyeth is now a wholly owned subsidiary of Pfizer48
Completed
Phase 1
Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy SubjectsHealthy
NCT00550381Wyeth is now a wholly owned subsidiary of Pfizer72